Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

被引：2
|
作者：
Chatterjee, Saurav [1 ]
Maitra, Subhankar [1 ]
Chakraborty, Anasua [2 ]
机构：
[1] Maimonides Hosp, Brooklyn, NY 11219 USA
[2] Univ Connecticut, Farmington, CT USA
来源：
AMERICAN HEART JOURNAL | 2012年 / 163卷 / 01期
关键词：
D O I：
10.1016/j.ahj.2011.10.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [1] Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Berger, Jeffrey S.
    Bhatt, Deepak L.
    Steg, P. Gabriel
    Steinhubl, Steven R.
    Montalescot, Gilles
    Shao, Mingyuan
    Hacke, Werner
    Fox, Keith A.
    Berger, Peter B.
    Topol, Eric J.
    Lincoff, A. Michael
    [J]. AMERICAN HEART JOURNAL, 2011, 162 (01) : 98 - U136
  • [2] Reply to the letter by Chatterjee et al "Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial"
    Berger, Jeffery S.
    Bhatt, Deepak L.
    [J]. AMERICAN HEART JOURNAL, 2012, 163 (01) : E3 - E3
  • [3] Clopidogrel for high atherothrombotic risk, ischemic stabilization, management, and avoidance (CHARISMA)
    不详
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (11) : CS6 - CS8
  • [4] A global view of atherothrombosis: Baseline characteristics in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial
    Bhatt, DL
    Fox, KA
    Hacke, W
    Berger, PB
    Black, HR
    Boden, WE
    Cacoub, P
    Cohen, EA
    Creager, MA
    Easton, JD
    Flather, MD
    Haffner, SM
    Hamm, CW
    Hankey, GJ
    Johnston, SC
    Mak, KH
    Mas, JL
    Montalescot, G
    Pearson, TA
    Steg, G
    Steinhubl, SR
    Weber, MA
    Booth, J
    Topol, EJ
    [J]. AMERICAN HEART JOURNAL, 2005, 150 (03) : 401.e1 - 401.e7
  • [5] Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study
    Mak, Koon-Hou
    Bhatt, Deepak L.
    Shao, Mingyuan
    Hankey, Graeme J.
    Easton, J. Donald
    Fox, Keith A. A.
    Topol, Eric J.
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (04) : 658 - 665
  • [6] Pravention atherothrombotischer ereignisse - CHARISMA-study (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance)
    Erdmann, E.
    [J]. INTERNIST, 2006, 47 (12): : 1295 - 1297
  • [7] The use of COX-2 inhibitors and the risk of myocardial infarction in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial
    Karha, Juhana
    Bhatt, Deepalk L.
    Wolski, Kathy
    Fox, Keith A.
    Montalescot, Gilles
    Topol, Eric J.
    [J]. CIRCULATION, 2006, 114 (18) : 814 - 814
  • [8] Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients A Prespecified Substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Trial
    Hankey, Graeme J.
    Hacke, Werner
    Easton, J. Donald
    Johnston, S. Claiborne
    Mas, Jean-Louis
    Brennan, Danielle M.
    Bhatt, Deepak L.
    Fox, Keith A. A.
    Topol, Eric J.
    [J]. STROKE, 2010, 41 (08) : 1679 - 1683
  • [9] Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Bhatt, DL
    Topol, EJ
    [J]. AMERICAN HEART JOURNAL, 2004, 148 (02) : 263 - 268
  • [10] Antiplatelet therapy in cerebrovascular disease: Implications of the management of artherothrombosis with clopidogrel in high-risk patients and the clopidogrel for high artherothrombotic risk and ischemic stabilization, management, and avoidance studies' results for cardiologists
    Fintel, Dan James
    [J]. CLINICAL CARDIOLOGY, 2007, 30 (12) : 604 - 614
12345